Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIC-2219
- Development stage
- Unknown
- Lead developer
- Immuno Cure Holding
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BIC-2219 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target the CD19 and CD22 antigens, which are both frequently expressed on the surface of B-cell malignancies. Developed by Beijing Imunocure Biotechnology, BIC-2219 is engineered to overcome the limitations of single-target CAR-T therapies, such as antigen escape and subsequent disease relapse. By dual-targeting CD19 and CD22, the therapy aims to achieve more durable remissions in patients with B-cell lineage cancers. It is currently being evaluated in clinical trials for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL), particularly in pediatric and adolescent populations.
- Other names
- CD19/CD22 dual-targeted CAR-T cellsBIC 2219BIC2219BIC-2219
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on BIC-2219.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIC-2219.